Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1991 Mar;213(3):190–198. doi: 10.1097/00000658-199103000-00002

Somatostatin and analogues in the treatment of cancer. A review.

B M Evers 1, D Parekh 1, C M Townsend Jr 1, J C Thompson 1
PMCID: PMC1358326  PMID: 1671812

Abstract

Somatostatin is a naturally occurring cyclic tetradecapeptide that inhibits release of growth hormone and all gastrointestinal hormones. The beneficial effect of somatostatin in the treatment of certain hypersecretory disorders of hormone excess in well recognized; however its clinical usefulness has been limited in the past by its extremely short plasma half-life. The development of long-acting somatostatin analogues has provided clinically useful agents for treatment of hormone-producing tumors. In addition to well-known inhibiting effects on hormone release and actions, recent studies using experimental tumor models have demonstrated an antiproliferative effect of somatostatin and its analogues on growth of a variety of neoplasms. The exact role of somatostatin analogues in cancer therapy has yet to be established; however studies suggest that these agents could provide a useful and relatively nontoxic adjuvant therapy in the treatment of certain tumors. In this review, the oncologic application of somatostatin and possible mechanism of action are examined and current clinical and experimental studies are summarized.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlman H., Ahlund L., Dahlström A., Nilsson O., Skolnik G., Tisell L. E., Tylén U. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. Br J Cancer. 1987 Dec;56(6):840–842. doi: 10.1038/bjc.1987.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alexander R. W., Upp J. R., Jr, Poston G. J., Gupta V., Townsend C. M., Jr, Thompson J. C. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res. 1988 Mar 15;48(6):1439–1441. [PubMed] [Google Scholar]
  3. Altimari A. F., Bhoopalam N., O'Dorsio T., Lange C. L., Sandberg L., Prinz R. A. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery. 1986 Dec;100(6):989–996. [PubMed] [Google Scholar]
  4. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T. J., Pless SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982 Sep 13;31(11):1133–1140. doi: 10.1016/0024-3205(82)90087-x. [DOI] [PubMed] [Google Scholar]
  5. Boden G., Ryan I. G., Eisenschmid B. L., Shelmet J. J., Owen O. E. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med. 1986 Jun 26;314(26):1686–1689. doi: 10.1056/NEJM198606263142606. [DOI] [PubMed] [Google Scholar]
  6. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–79. doi: 10.1126/science.179.4068.77. [DOI] [PubMed] [Google Scholar]
  7. Cai R. Z., Szoke B., Lu R., Fu D., Redding T. W., Schally A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896–1900. doi: 10.1073/pnas.83.6.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Catane R., Lichter A., Lee Y. J., Brereton H. D., Schwade J. G., Glatstein E. Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer. 1981 Nov 1;48(9):1936–1943. doi: 10.1002/1097-0142(19811101)48:9<1936::aid-cncr2820480904>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  9. Clements D., Elias E. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet. 1985 Apr 13;1(8433):874–875. doi: 10.1016/s0140-6736(85)92235-4. [DOI] [PubMed] [Google Scholar]
  10. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  11. Davies R. R., Miller M., Turner S. J., Goodship T. H., Cook D. B., Watson M., McGill A., Orskov H., Alberti K. G., Johnston D. G. Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol (Oxf) 1986 Jun;24(6):665–674. doi: 10.1111/j.1365-2265.1986.tb01663.x. [DOI] [PubMed] [Google Scholar]
  12. Ellison E. C., O'Dorisio T. M., Sparks J., Mekhjian H. S., Fromkes J. J., Woltering E. A., Carey L. C. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas. Surgery. 1986 Aug;100(2):437–444. [PubMed] [Google Scholar]
  13. Erisman M. D., Linnoila R. I., Hernandez O., DiAugustine R. P., Lazarus L. H. Human lung small-cell carcinoma contains bombesin. Proc Natl Acad Sci U S A. 1982 Apr;79(7):2379–2383. doi: 10.1073/pnas.79.7.2379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  15. Hierowski M. T., Liebow C., du Sapin K., Schally A. V. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett. 1985 Jan 7;179(2):252–256. doi: 10.1016/0014-5793(85)80529-9. [DOI] [PubMed] [Google Scholar]
  16. Juby L. D., Burke D. A., Axon A. T. Somatostatin analogue SMS 201-995 long term therapy for vipoma. Postgrad Med J. 1987 Apr;63(738):287–289. doi: 10.1136/pgmj.63.738.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kraenzlin M. E., Ch'ng J. L., Wood S. M., Carr D. H., Bloom S. R. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology. 1985 Jan;88(1 Pt 1):185–187. doi: 10.1016/s0016-5085(85)80153-0. [DOI] [PubMed] [Google Scholar]
  18. Krejs G. J. Gastrointestinal endocrine tumors. Am J Med. 1987 May 29;82(5B):1–3. doi: 10.1016/0002-9343(87)90421-9. [DOI] [PubMed] [Google Scholar]
  19. Krulich L., Dhariwal A. P., McCann S. M. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology. 1968 Oct;83(4):783–790. doi: 10.1210/endo-83-4-783. [DOI] [PubMed] [Google Scholar]
  20. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  21. Lamberts S. W., Koper J. W., Reubi J. C. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest. 1987 Aug;17(4):281–287. doi: 10.1111/j.1365-2362.1987.tb02188.x. [DOI] [PubMed] [Google Scholar]
  22. Lamberts S. W., Reubi J. C., Uiterlinden P., Zuiderwijk J., van den Werff P., van Hal P. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology. 1986 Jun;118(6):2188–2194. doi: 10.1210/endo-118-6-2188. [DOI] [PubMed] [Google Scholar]
  23. Lamberts S. W., Uitterlinden P., del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 1987 Oct;65(4):703–710. doi: 10.1210/jcem-65-4-703. [DOI] [PubMed] [Google Scholar]
  24. Liebow C., Hierowski M., duSapin K. Hormonal control of pancreatic cancer growth. Pancreas. 1986;1(1):44–48. doi: 10.1097/00006676-198601000-00009. [DOI] [PubMed] [Google Scholar]
  25. Lippman M. E., Dickson R. B., Kasid A., Gelmann E., Davidson N., McManaway M., Huff K., Bronzert D., Bates S., Swain S. Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem. 1986 Jan;24(1):147–154. doi: 10.1016/0022-4731(86)90044-0. [DOI] [PubMed] [Google Scholar]
  26. Longnecker S. M. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharm. 1988 Feb;22(2):99–106. doi: 10.1177/106002808802200201. [DOI] [PubMed] [Google Scholar]
  27. Lucey M. R. Endogenous somatostatin and the gut. Gut. 1986 Apr;27(4):457–467. doi: 10.1136/gut.27.4.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mascardo R. N., Sherline P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology. 1982 Oct;111(4):1394–1396. doi: 10.1210/endo-111-4-1394. [DOI] [PubMed] [Google Scholar]
  29. Maton P. N., Gardner J. D., Jensen R. T. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989 Mar;34(3 Suppl):28S–39S. doi: 10.1007/BF01536043. [DOI] [PubMed] [Google Scholar]
  30. Moody T. W., Bertness V., Carney D. N. Bombesin-like peptides and receptors in human tumor cell lines. Peptides. 1983 Sep-Oct;4(5):683–686. doi: 10.1016/0196-9781(83)90018-9. [DOI] [PubMed] [Google Scholar]
  31. Murphy W. A., Lance V. A., Moreau S., Moreau J. P., Coy D. H. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci. 1987 Jun 29;40(26):2515–2522. doi: 10.1016/0024-3205(87)90073-7. [DOI] [PubMed] [Google Scholar]
  32. O'Dorisio T. M., Gaginella T. S., Mekhjian H. S., Rao B., O'Dorisio M. S. Somatostatin and analogues in the treatment of VIPoma. Ann N Y Acad Sci. 1988;527:528–535. doi: 10.1111/j.1749-6632.1988.tb27006.x. [DOI] [PubMed] [Google Scholar]
  33. Osei K., O'Dorisio T. M. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones. Ann Intern Med. 1985 Aug;103(2):223–225. doi: 10.7326/0003-4819-103-2-223. [DOI] [PubMed] [Google Scholar]
  34. Price B. A., Jaffe B. M., Zinner M. J. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. Gastroenterology. 1985 Jan;88(1 Pt 1):80–85. doi: 10.1016/s0016-5085(85)80136-0. [DOI] [PubMed] [Google Scholar]
  35. Redding T. W., Schally A. V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A. 1984 Jan;81(1):248–252. doi: 10.1073/pnas.81.1.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med. 1987 Mar;109(3):320–326. [PubMed] [Google Scholar]
  37. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  38. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  39. Reubi J. C. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985 May;109(1):108–114. doi: 10.1530/acta.0.1090108. [DOI] [PubMed] [Google Scholar]
  40. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  41. Rose D. P., Gottardis M., Noonan J. J. Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin. Anticancer Res. 1983 Sep-Oct;3(5):323–325. [PubMed] [Google Scholar]
  42. Rydning A., Berstad A. Dietary fiber and peptic ulcer. Scand J Gastroenterol. 1986 Jan;21(1):1–5. [PubMed] [Google Scholar]
  43. Santangelo W. C., O'Dorisio T. M., Kim J. G., Severino G., Krejs G. J. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med. 1985 Sep;103(3):363–367. doi: 10.7326/0003-4819-103-3-363. [DOI] [PubMed] [Google Scholar]
  44. Scambia G., Panici P. B., Baiocchi G., Perrone L., Iacobelli S., Mancuso S. Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol. 1988;114(3):306–308. doi: 10.1007/BF00405839. [DOI] [PubMed] [Google Scholar]
  45. Schally A. V., Comaru-Schally A. M., Redding T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med. 1984 Mar;175(3):259–281. doi: 10.3181/00379727-175-41797. [DOI] [PubMed] [Google Scholar]
  46. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  47. Schally A. V., Redding T. W. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7275–7279. doi: 10.1073/pnas.84.20.7275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Setyono-Han B., Henkelman M. S., Foekens J. A., Klijn G. M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res. 1987 Mar 15;47(6):1566–1570. [PubMed] [Google Scholar]
  49. Shepherd J. J., Senator G. B. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet. 1986 Sep 6;2(8506):574–574. doi: 10.1016/s0140-6736(86)90139-x. [DOI] [PubMed] [Google Scholar]
  50. Smith J. P., Solomon T. E. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology. 1988 Dec;95(6):1541–1548. doi: 10.1016/s0016-5085(88)80075-1. [DOI] [PubMed] [Google Scholar]
  51. Sorenson G. D., Bloom S. R., Ghatei M. A., Del Prete S. A., Cate C. C., Pettengill O. S. Bombesin production by human small cell carcinoma of the lung. Regul Pept. 1982 Jul;4(2):59–66. doi: 10.1016/0167-0115(82)90095-7. [DOI] [PubMed] [Google Scholar]
  52. Souquet J. C., Sassolas G., Forichon J., Champetier P., Partensky C., Chayvialle J. A. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer. 1987 May 1;59(9):1654–1660. doi: 10.1002/1097-0142(19870501)59:9<1654::aid-cncr2820590922>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  53. Spring-Mills E. J., Stearns S. B., Numann P. J., Smith P. H. Immunocytochemical localization of insulin- and somatostatin-like material in human breast tumors. Life Sci. 1984 Jul 9;35(2):185–190. doi: 10.1016/0024-3205(84)90138-3. [DOI] [PubMed] [Google Scholar]
  54. Taylor J. E., Bogden A. E., Moreau J. P., Coy D. H. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun. 1988 May 31;153(1):81–86. doi: 10.1016/s0006-291x(88)81192-6. [DOI] [PubMed] [Google Scholar]
  55. Tydén G., Samnegård H., Thulin L., Muhrbeck O., Efendić S. Circulatory effects of somatostatin in anesthetized man. Acta Chir Scand. 1979;145(7):443–446. [PubMed] [Google Scholar]
  56. Upp J. R., Jr, Olson D., Poston G. J., Alexander R. W., Townsend C. M., Jr, Thompson J. C. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg. 1988 Jan;155(1):29–35. doi: 10.1016/s0002-9610(88)80254-x. [DOI] [PubMed] [Google Scholar]
  57. Upp J. R., Jr, Singh P., Townsend C. M., Jr, Thompson J. C. Clinical significance of gastrin receptors in human colon cancers. Cancer Res. 1989 Jan 15;49(2):488–492. [PubMed] [Google Scholar]
  58. Vinik A. I., Tsai S., Moattari A. R., Cheung P. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery. 1988 Nov;104(5):834–842. [PubMed] [Google Scholar]
  59. Walsh J. H., Reeve J. R., Jr Mammalian bombesin-like peptides: neuromodulators of gastric function and autocrine regulators of lung cancer growth. Peptides. 1985;6 (Suppl 3):63–68. doi: 10.1016/0196-9781(85)90352-3. [DOI] [PubMed] [Google Scholar]
  60. Weber C., Merriam L., Koschitzky T., Karp F., Benson M., Forde K., LoGerfo P. Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery. 1989 Aug;106(2):416–422. [PubMed] [Google Scholar]
  61. Werner H., Amarant T., Millar R. P., Fridkin M., Koch Y. Immunoreactive and biologically active somatostatin in human and sheep milk. Eur J Biochem. 1985 Apr 15;148(2):353–357. doi: 10.1111/j.1432-1033.1985.tb08846.x. [DOI] [PubMed] [Google Scholar]
  62. Wiedenmann B., Räth U., Rädsch R., Becker F., Kommerell B. Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wochenschr. 1988 Jan 15;66(2):75–77. doi: 10.1007/BF01713015. [DOI] [PubMed] [Google Scholar]
  63. Williams G., Anderson J. V., Williams S. J., Bloom S. R. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion. Acta Endocrinol Suppl (Copenh) 1987;286:26–36. [PubMed] [Google Scholar]
  64. Williams G., Ball J. A., Burrin J. M., Joplin G. F., Bloom S. R. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet. 1986 Oct 4;2(8510):774–778. doi: 10.1016/s0140-6736(86)90300-4. [DOI] [PubMed] [Google Scholar]
  65. Winsett O. E., Townsend C. M., Jr, Glass E. J., Thompson J. C. Gastrin stimulates growth of colon cancer. Surgery. 1986 Mar;99(3):302–307. [PubMed] [Google Scholar]
  66. Wood S. M., Wood J. R., Ghatei M. A., Lee Y. C., O'Shaughnessy D., Bloom S. R. Bombesin, somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma. J Clin Endocrinol Metab. 1981 Dec;53(6):1310–1312. doi: 10.1210/jcem-53-6-1310. [DOI] [PubMed] [Google Scholar]
  67. Yoshizaki K., de Bock V., Takai I., Wang N. S., Solomon S. Bombesin-like peptides in human small cell carcinoma of the lung. Regul Pept. 1986 Mar;14(1):11–20. doi: 10.1016/0167-0115(86)90201-6. [DOI] [PubMed] [Google Scholar]
  68. Zalatnai A., Paz-Bouza J. I., Redding T. W., Schally A. V. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Prostate. 1988;12(1):85–98. doi: 10.1002/pros.2990120111. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES